Benzinga

Benzinga

Benzinga

domenica, settembre 06

Gilead Sciences Inc

GILDNASDAQ
Trade with Public
Trade with Public
$151.00
-0.22-0.15%
In chiusura: Sep 4, 5:00 PM EST
$149.77
-1.23-0.81%
Post-mercato: Sep 4, 4:43 PM EST
Dividendo: La data di stacco del dividendo è tra 10 giorni
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoDividendiConfrontaOpzioniRapporto azionario

Gilead Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Gilead Sciences (GILD).

Price Target Range — 8 Quarters

Analyst Consensus — 23 Analysts

19Buy
4Hold
Consensus RatingBuy# Analysts23Avg. Consensus PT$135Upside to Avg. PT-9.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 5, 2026RBC CapitalBrian AbrahamsPT RaiseSector Perform$120→$123
Aug 5, 2026Cantor FitzgeraldCarter GouldMaintainedOverweight$155
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
CNBC Halftime Report Final Trades: Airbnb, Gilead Sciences, KLA, Snowflake

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $123

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $120 to $123.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price Target

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and maintains $170 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $145

Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price target from $155 to $145.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $165

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $166 to $165.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved